Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa

[1]  G. V. van Dongen,et al.  Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  P. Ascierto,et al.  Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program , 2020, Journal for ImmunoTherapy of Cancer.

[3]  J. Schlom,et al.  Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances , 2020, Journal for ImmunoTherapy of Cancer.

[4]  Saburo Ito,et al.  Cryo-EM Reveals Integrin-Mediated TGF-β Activation without Release from Latent TGF-β , 2020, Cell.

[5]  C. H. Nielsen,et al.  Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  A. Ravaud,et al.  Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial , 2019, Journal of Immunotherapy for Cancer.

[7]  K. Kelly,et al.  Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial , 2019, JAMA oncology.

[8]  F. Giles,et al.  Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) , 2018, Journal of Immunotherapy for Cancer.

[9]  J. Schlom,et al.  M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine , 2018, Oncoimmunology.

[10]  Camille Stephan-Otto Attolini,et al.  TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis , 2018, Nature.

[11]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[12]  Aroop Sircar,et al.  Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β , 2018, Science Translational Medicine.

[13]  J. Schlom,et al.  Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors , 2018, Clinical Cancer Research.

[14]  J. Schlom,et al.  Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824) , 2017, Oncotarget.

[15]  Jaime Rodriguez-Canales,et al.  Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[16]  G. Sgouros,et al.  Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma , 2017, The Journal of Nuclear Medicine.

[17]  A. Ravaud,et al.  Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Bourgon,et al.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , 2017, The Lancet.

[19]  Wojciech G. Lesniak,et al.  PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET. , 2016, Bioconjugate chemistry.

[20]  M. Bartholomä,et al.  High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers , 2016, Theranostics.

[21]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[22]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[23]  K. Steele,et al.  Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. , 2016, The Lancet. Oncology.

[24]  H. Koeppen,et al.  Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor , 2016, mAbs.

[25]  Wojciech G. Lesniak,et al.  A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors , 2016, Oncotarget.

[26]  George Sgouros,et al.  Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer. , 2016, Cancer research.

[27]  Xue Han,et al.  Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.

[28]  Yiping Yang,et al.  Cancer immunotherapy: harnessing the immune system to battle cancer. , 2015, The Journal of clinical investigation.

[29]  J. Galon,et al.  From mice to humans: developments in cancer immunoediting. , 2015, The Journal of clinical investigation.

[30]  W. Oyen,et al.  Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. , 2015, Cancer research.

[31]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[32]  C Le Loirec,et al.  Positron range in PET imaging: non-conventional isotopes , 2014, Physics in medicine and biology.

[33]  R. Weiskirchen,et al.  Immunomodulatory effects of transforming growth factor-β in the liver. , 2014, Hepatobiliary surgery and nutrition.

[34]  C. L. Loirec,et al.  Positron range in PET imaging: an alternative approach for assessing and correcting the blurring , 2012, Physics in medicine and biology.

[35]  D. Abou,et al.  In vivo biodistribution and accumulation of 89Zr in mice. , 2011, Nuclear medicine and biology.

[36]  R. Goldschmeding,et al.  Expression patterns of connective tissue growth factor and of TGF-beta isoforms during glomerular injury recapitulate glomerulogenesis. , 2010, American journal of physiology. Renal physiology.

[37]  P. Jurek,et al.  Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine , 2010, Nature Protocols.

[38]  P. Loke,et al.  B7x: A widely expressed B7 family member that inhibits T cell activation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Scott,et al.  Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts. , 2001, Cancer research.

[40]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[41]  L. Lucy.  An iterative technique for the rectification of observed distributions , 1974 .

[42]  S. Ogawa,et al.  Signal Transduction Via Co-stimulatory and Co-inhibitory Receptors. , 2019, Advances in experimental medicine and biology.

[43]  A. Nebreda,et al.  TGF ‐ beta drives immune evasion in genetically reconstituted colon cancer metastasis , 2018 .

[44]  E. Jaffee,et al.  Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.

[45]  William H. Richardson,et al.  Bayesian-Based Iterative Method of Image Restoration , 1972 .